{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:45:42Z","timestamp":1771602342474,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China (973 Program)","doi-asserted-by":"crossref","award":["2015CB755400"],"award-info":[{"award-number":["2015CB755400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2009SC0066"],"award-info":[{"award-number":["2009SC0066"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The information concerning non-invasive, easily obtainable, and accurate biomarkers for diagnosis of lupus nephritis (LN) is extremely limited. The aim of this study was to evaluate the diagnostic performance of cystatin C (CysC) and complement component 1q (C1q) for LN.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A case-control study that included 905 patients with systemic lupus erythematosus (SLE) without LN (group SLE), 334 patients with active lupus nephritis (group LNA), 255 patients with inactive lupus nephritis (group LNI), and 497 healthy individuals (group HC) was performed in Mianyang Central Hospital from March 2017 to December 2018. The serum levels of CysC, C1q, urea (Urea), and creatinine (Creat) were measured, and 2 estimated glomerular filtration rates (eGFR<jats:sub>CysC<\/jats:sub> and eGFR<jats:sub>Creat<\/jats:sub>) were calculated by equations which were based on serum CysC established by our group and the modification of diet in renal disease (MDRD), respectively. ANOVA analysis or Kruskal-Wallis test was used for comparing the differences among the groups, and receiver operating characteristic (ROC) curve was applied to identify the diagnostic efficiencies of individual or combined multiple indicators.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Significantly elevated CysC and decreased C1q were observed in the LNA and LNI groups, which was in contrast to their levels in the SLE and HC groups. CysC (AUC\u2009=\u20090.906) or eGFR<jats:sub>CysC<\/jats:sub> (AUC\u2009=\u20090.907) assessed the highest diagnostic performance on LNA when detected individually, followed by C1q (AUC\u2009=\u20090.753). Joint utilization of C1q and CysC achieved very good performance (AUC\u2009=\u20090.933) which approximated to the best one observed in the combinations of C1q, Urea, CysC, eGFR<jats:sub>Creat<\/jats:sub>, and Creat (AUC\u2009=\u20090.975).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The separately detected CysC (eGFR<jats:sub>CysC<\/jats:sub>) and C1q were superior to the conventional biomarkers Urea, Creat, and eGFR<jats:sub>Creat<\/jats:sub> in the diagnosis of LNA. Moreover, although the combined detection of Urea, Creat, C1q, CysC, and eGFR<jats:sub>Creat<\/jats:sub> had the greatest diagnostic performance, the joint utilization of CysC and C1q could be prioritized for rapid discrimination of LNA if the economic burden is taken into consideration.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13075-019-2065-x","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T19:03:28Z","timestamp":1575486208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diagnostic performance of serum cystatin C and complement component 1q in lupus nephritis"],"prefix":"10.1186","volume":"21","author":[{"given":"Bei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-041X","authenticated-orcid":false,"given":"Ya-mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-fu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"2065_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/OARRR.S112829","volume":"8","author":"Y Chia-Li","year":"2016","unstructured":"Chia-Li Y, Song-Chou H, Chang-Youh T. Potential serum and urine biomarkers in patients with lupus nephritis and the unsolved problems. Open Access Rheumatol. 2016;8:81\u201391.","journal-title":"Open Access Rheumatol"},{"issue":"4","key":"2065_CR2","first-page":"369","volume":"49","author":"LA Bawazier","year":"2017","unstructured":"Bawazier LA. Current and emerging therapy on lupus nephritis. Acta Med Indones. 2017;49(4):369\u201377.","journal-title":"Acta Med Indones"},{"key":"2065_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1177\/0961203318758507","volume":"27","author":"XW Dong","year":"2018","unstructured":"Dong XW, Zheng ZH, Ding J, Luo X, Li ZQ, Li Y, et al. Combined detection of uMCP-1 and uTWEAK for rapid discrimination of severe lupus nephritis. Lupus. 2018;27:971\u201381.","journal-title":"Lupus"},{"key":"2065_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-015-1179-y","volume":"20","author":"TF Imran","year":"2016","unstructured":"Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S, et al. Lupus nephritis: an update. Clin Exp Nephrol. 2016;20:1\u201313.","journal-title":"Clin Exp Nephrol"},{"key":"2065_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12:825\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2065_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/ndt\/gfv102","volume":"31","author":"S Wilhelmus","year":"2016","unstructured":"Wilhelmus S, Bajema IM, Bertsias GK, Boumpas DT, Gordon C, Lightstone L, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016;31:904\u201313.","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"2065_CR7","doi-asserted-by":"publisher","first-page":"e11287","DOI":"10.1097\/MD.0000000000011287","volume":"97","author":"Y Wang","year":"2018","unstructured":"Wang Y, Tao Y, Liu Y, Zhao Y, Song C, Zhou B, et al. Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity. Medicine (Baltimore). 2018;97(26):e11287.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2065_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1574884713666180403150359","volume":"13","author":"F Aziz","year":"2018","unstructured":"Aziz F, Chaudhary K. Lupus nephritis: a treatment update. Curr Clin Pharmacol. 2018;13(1):4\u201313.","journal-title":"Curr Clin Pharmacol"},{"key":"2065_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4172\/2161-0681.1000352","volume":"8","author":"A Khairwa","year":"2018","unstructured":"Khairwa A. Role of urinary biomarkers for diagnosis of lupus nephritis. J Clin Exp Pathol. 2018;8:4.","journal-title":"J Clin Exp Pathol"},{"key":"2065_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3899\/jrheum.110532","volume":"39","author":"D Wakasugi","year":"2012","unstructured":"Wakasugi D, Gono T, Kawaguchi Y, Hara M, Koseki Y, Katsumata Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol. 2012;39:79\u201385.","journal-title":"J Rheumatol"},{"issue":"4","key":"2065_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40620-016-0313-6","volume":"29","author":"G Moroni","year":"2016","unstructured":"Moroni G, Raffiotta F, Ponticelli C. Remission and withdrawal of therapy in lupus nephritis. J Nephrol. 2016;29(4):559\u201365.","journal-title":"J Nephrol"},{"issue":"1","key":"2065_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12882-017-0508-7","volume":"18","author":"A Loesment-Wendelmuth","year":"2017","unstructured":"Loesment-Wendelmuth A, Schaeffner E, Ebert N. Two elderly patients with normal creatinine and elevated cystatin C - a case report. BMC Nephrol. 2017;18(1):87.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2065_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.31053\/1853.0605.v74.n3.14814","volume":"74","author":"GI Medina Arnaudo","year":"2017","unstructured":"Medina Arnaudo GI. Evaluation of equations using cystatin C for estimation of the glomerular filtration rate in healthy adult population of canidates for kidney donors. Rev Fac Cien Med Univ Nac Cordoba. 2017;74(3):243\u201350.","journal-title":"Rev Fac Cien Med Univ Nac Cordoba"},{"key":"2065_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1053\/j.ajkd.2012.03.011","volume":"60","author":"S Waheed","year":"2012","unstructured":"Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, et al. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2012;60:207\u201316.","journal-title":"Am J Kidney Dis"},{"key":"2065_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1214234","volume":"369","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Matsushita K, \u00c4rnl\u00f6v J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932\u201343.","journal-title":"N Engl J Med"},{"key":"2065_CR16","doi-asserted-by":"publisher","unstructured":"Osaki T, Satoh M, Tanaka F, Tanno K, Takahashi Y, Nasu T, et al. The value of a cystatin C-based estimated glomerular filtration rate for cardiovascular assessment in a general Japanese population: results from the Iwate Tohoku Medical Megabank Project. J Epidemiol. 2019. https:\/\/doi.org\/10.2188\/jea.JE20180274.","DOI":"10.2188\/jea.JE20180274"},{"key":"2065_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1681\/ASN.2010050483","volume":"22","author":"CA Peralta","year":"2011","unstructured":"Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147\u201355.","journal-title":"J Am Soc Nephrol"},{"key":"2065_CR18","doi-asserted-by":"publisher","first-page":"e57240","DOI":"10.1371\/journal.pone.0057240","volume":"8","author":"JF Feng","year":"2013","unstructured":"Feng JF, Qiu L, Zhang L, Li XM, Yang YW, Zeng P, et al. Multicenter study of creatinine and\/or cystatin C-based equations for estimation of glomerular filtration rates in Chinese patients with chronic kidney disease. PLoS One. 2013;8:e57240.","journal-title":"PLoS One"},{"issue":"9","key":"2065_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538\u201347.","journal-title":"Nat Rev Rheumatol"},{"key":"2065_CR20","first-page":"OC39","volume":"11","author":"J Kabeerdoss","year":"2017","unstructured":"Kabeerdoss J, Gupta N, Pulukool S, Mohan H, Mahasampath G, Danda D. Anti-C1q antibody is associated with renal and cutaneous manifestations in Asian Indian patients with systemic lupus erythematosus. J Clin Diagn Res. 2017;11:OC39\u201342.","journal-title":"J Clin Diagn Res"},{"key":"2065_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molimm.2015.03.007","volume":"67","author":"M Stegert","year":"2015","unstructured":"Stegert M, Bock M, Trendelenburg M. Clinical presentation of human C1q deficiency: how much of a lupus? Mol Immunol. 2015;67:3\u201311.","journal-title":"Mol Immunol"},{"key":"2065_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s10067-012-2017-1","volume":"31","author":"Z Chen","year":"2012","unstructured":"Chen Z, Wang GS, Wang GH, Li XP. Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis. Clin Rheumatol. 2012;31:1323\u20139.","journal-title":"Clin Rheumatol"},{"key":"2065_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.amjms.2017.01.005","volume":"353","author":"D Song","year":"2017","unstructured":"Song D, Guo WY, Wang FM, Li YZ, Song Y, Yu F, et al. Complement alternative pathway\u2019s activation in patients with lupus nephritis. Am J Med Sci. 2017;353:247\u201357.","journal-title":"Am J Med Sci"},{"key":"2065_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2369-14-63","volume":"14","author":"Y Tan","year":"2013","unstructured":"Tan Y, Song D, Wu LH, Yu F, Zhao MH. Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis. BMC Nephrol. 2013;14:63.","journal-title":"BMC Nephrol"},{"key":"2065_CR25","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/1529-0131(199901)42:1<189::AID-ANR26>3.0.CO;2-M","volume":"42","author":"DD Gladman","year":"1999","unstructured":"Gladman DD, Urowitz MB, Esdaile JM, Hahn BH, Klippel J, Lahita R, et al. Guidelines for referral and management of systemic lupus erythematous in adults. Arthritis Rheum. 1999;42:1785\u201396.","journal-title":"Arthritis Rheum"},{"key":"2065_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797\u2013808.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2065_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630\u201340.","journal-title":"Arthritis Rheum"},{"key":"2065_CR28","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","volume":"17","author":"YC Ma","year":"2006","unstructured":"Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937\u201344.","journal-title":"J Am Soc Nephrol"},{"key":"2065_CR29","volume-title":"Renal function tests. StatPearls","author":"V Gounden","year":"2019","unstructured":"Gounden V, Jialal I. Renal function tests. StatPearls. Treasure Island: StatPearls Publishing; 2019."},{"key":"2065_CR30","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s10067-017-3837-9","volume":"36","author":"P Garcia-Garcia","year":"2017","unstructured":"Garcia-Garcia P, Castejon R, Tutor-Ureta P, Silvestre RA, Mellor-Pita S, Jimenez-Ortiz C, et al. Serum cystatin C is associated with kidney function but not with cardiovascular risk factors or subclinical atherosclerosis in patients with systemic lupus erythematous. Clin Rheumatol. 2017;36:2709\u201317.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"2065_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/jcph.1132","volume":"58","author":"S Kar","year":"2018","unstructured":"Kar S, Paglialunga S, Islam R. Cystatin C is a more reliable biomarker for determining eGFR to support drug development studies. J Clin Pharmacol. 2018;58(10):1239\u201347.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2065_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MNH.0000000000000115","volume":"24","author":"TW Ferguson","year":"2015","unstructured":"Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295\u2013300.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2065_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cca.2019.04.069","volume":"495","author":"MZ Bidin","year":"2019","unstructured":"Bidin MZ, Shah AM, Stanslas J, Seong CLT. Blood and urine biomarkers in chronic kidney disease: an update. Clin Chim Acta. 2019;495:239\u201350.","journal-title":"Clin Chim Acta"},{"key":"2065_CR34","doi-asserted-by":"publisher","first-page":"e6949","DOI":"10.1097\/MD.0000000000006949","volume":"96","author":"D Wang","year":"2017","unstructured":"Wang D, Feng JF, Wang AQ, Yang YW, Liu YS. Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients. Medicine. 2017;96:e6949.","journal-title":"Medicine."},{"key":"2065_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bios.2018.11.031","volume":"126","author":"CS Pundir","year":"2019","unstructured":"Pundir CS, Kumar P, Jaiwal R. Biosensing methods for determination of creatinine: a review. Biosens Bioelectron. 2019;126:707\u201324.","journal-title":"Biosens Bioelectron"},{"key":"2065_CR36","doi-asserted-by":"publisher","first-page":"450351","DOI":"10.1155\/2015\/450351","volume":"2015","author":"S Chi","year":"2015","unstructured":"Chi S, Yu Y, Shi J, Zhang Y, Yang J, Yang L, et al. Antibodies against C1q are a valuable serological marker for identification of systemic lupus erythematosus patients with active lupus nephritis. Dis Markers. 2015;2015:450351.","journal-title":"Dis Markers"},{"key":"2065_CR37","first-page":"1390","volume":"17","author":"C Qu","year":"2019","unstructured":"Qu C, Zhang J, Zhang X, Du J, Su B, Li H. Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus. Exp Ther Med. 2019;17:1390\u20134.","journal-title":"Exp Ther Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-2065-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T02:11:36Z","timestamp":1606961496000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-2065-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-2065-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all participants, and clinical data, urine, and serum samples were collected and analyzed only for research. The study was approved by the Medical Ethics Committee (Institutional Review Board) of Mianyang Central Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}